PANTHERx Rare Partners with Upsher-Smith for VIGAFYDE Distribution
PANTHERx Rare is thrilled to announce its selection by Upsher-Smith Laboratories, LLC as the specialist pharmacy responsible for distributing VIGAFYDE™ (vigabatrin), a concentrated oral solution aimed at treating infants diagnosed with infantile spasms. This medication has been approved for use in pediatric patients aged one month to two years, where the advantages of treatment surpass the risks of vision loss.
Understanding Infantile Spasms and Their Impact
Infantile spasms are a rare and serious neurological condition that manifests as clusters of brief seizures accompanied by stiffening of muscles in various parts of the infant's body. This complex disorder commonly presents in infants from three to eight months old, with many experiencing resolution by ages two to four. However, these spasms can often be linked to underlying issues, such as brain injuries or genetic disorders.
Timely diagnosis and intervention are crucial for infants experiencing spasms, as failing to address the condition can lead to serious long-term complications, including developmental delays and an increased risk of conditions like epilepsy, intellectual disabilities, or autism.
PANTHERx Rare's Commitment to Pediatric Patients
Rob Snyder, Executive Chairman of PANTHERx Rare Pharmacy, shared insights about the challenges faced by families whose children are diagnosed with infantile spasms. "Parents of these infants often struggle with numerous concerns regarding their child's health and well-being. At PANTHERx, we have extensive experience in assisting these families to ensure that medications reach them promptly, enabling their infants to transition from hospital care to home quickly and safely," he remarked.
He further emphasized the importance of their collaboration with Upsher-Smith, expressing optimism about the impact it will have on the lives of babies suffering from this condition.
About PANTHERx Rare Pharmacy
PANTHERx Rare is dedicated solely to serving those with rare and orphan diseases. Recognized as The Rare Disease Pharmacy®, it focuses on ensuring that individuals have access to groundbreaking medicine, instructional support, and vital resources. By prioritizing patient needs, PANTHERx is proud to have received multiple accolades, including the esteemed MMIT Patient Choice Award, representing its commitment to excellence in patient satisfaction.
With dual accreditations for orphan drugs and a distinction as a Rare Disease Center of Excellence, PANTHERx operates across all 50 states and U.S. territories, striving to meet the needs of a broad range of patients.
VIGAFYDE: An Essential Medication
VIGAFYDE is produced by Pyros Pharmaceuticals, Inc. and has been developed specifically for the treatment of infantile spasms. Its ready-to-use formulation makes it a vital tool in managing the condition effectively.
FAQs
What is VIGAFYDE?
VIGAFYDE is an oral solution prescribed for treating infantile spasms in young children, providing essential support to those affected by the condition.
Who can benefit from VIGAFYDE?
This medication is suitable for infants between one month and two years old who are diagnosed with infantile spasms and where the potential benefits of treatment outweigh the risks.
Why is timely treatment important for infantile spasms?
Early diagnosis and treatment can help prevent serious long-term effects, such as developmental delays and other neurological complications.
What role does PANTHERx Rare play in patient care?
PANTHERx Rare serves as a specialty pharmacy focused on supplying medications and support services for individuals with rare diseases, ensuring they receive timely access to critical treatments.
How can I contact PANTHERx Rare for more information?
For additional queries, individuals can reach out to PANTHERx Rare directly through their official communications channels, ensuring they receive necessary information tailored to their needs.
